Sleep Apnea Pill Developer Apnimed To Go Public On Nasdaq At $16 Per Share

Source Summary

Apnimed Inc. is expected to begin trading on the Nasdaq Global Select Market, under the ticker symbol APMD, today, July 31, 2026. This late-stage clinical pharmaceutical company is developing novel oral therapies that address the neurobiology of sleep-related breathing diseases.